Cargando…

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1(st)-Line Treatment for Non-Small-Cell Lung Cancer

Platinum-based chemotherapy has long been the first-line treatment of choice for metastatic non-small-cell lung cancer (NSCLC) patients who lack targetable gene mutations. The arrival of checkpoint blockade has led to a vast shift in the treatment landscape of NSCLC. Among NSCLC patients with PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chongkai, Kulkarni, Prakash, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444295/ https://www.ncbi.nlm.nih.gov/pubmed/30976658 http://dx.doi.org/10.1016/j.omto.2019.02.001

Ejemplares similares

Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors
por: Salgia, Ravi
Publicado: (2014)

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
por: Puri, Neelu, et al.
Publicado: (2008)

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
por: Rajurkar, Swapnil, et al.
Publicado: (2020)

Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research
por: Subbiah, Shanmuga, et al.
Publicado: (2020)

Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy
por: Nam, Arin, et al.
Publicado: (2021)

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
por: Villaflor, Victoria M., et al.
Publicado: (2013)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Integrating Clinical and Translational Research Networks—Building Team Medicine
por: Salgia, Ravi, et al.
Publicado: (2020)

On the Virtues of “Team Medicine”—A City of Hope Perspective
por: Kulkarni, Prakash, et al.
Publicado: (2023)

Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
por: Qiu, Lupeng, et al.
Publicado: (2022)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

Intrinsically disordered proteins and conformational noise: The hypothesis a decade later
por: Kulkarni, Prakash, et al.
Publicado: (2023)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
por: Ramisetty, Sravani, et al.
Publicado: (2023)

Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma
por: Salgia, Ravi
Publicado: (2016)

Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non–Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection
por: Wasilewski, David, et al.
Publicado: (2022)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer
por: Hewelt, Blake, et al.
Publicado: (2019)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2022)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers
por: Choudhury, Noura J., et al.
Publicado: (2021)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology
por: Mambetsariev, Isa, et al.
Publicado: (2019)

Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?
por: Kanwal, Bushra, et al.
Publicado: (2018)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Combined immune checkpoint inhibitor and chemotherapy is effective in a patient with ALK rearranged non-small cell lung cancer: a case report
por: Xia, Lexin, et al.
Publicado: (2020)

Multiparameter prediction model of immune checkpoint inhibitors combined with chemotherapy for non-small cell lung cancer based on support vector machine learning
por: Zhou, Zihan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6uq93larsab22iskdjlnf9gb1e